Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. More Details
Concerning outlook with weak fundamentals.
Share Price & News
How has Progenity's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PROG is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: PROG's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how PROG performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how PROG performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Progenity's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StEarnings Release: Here's Why Analysts Cut Their Progenity, Inc. (NASDAQ:PROG) Price Target To US$8.00
2 months ago | Simply Wall StIs Progenity, Inc. (NASDAQ:PROG) Popular Amongst Insiders?
Is Progenity undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Progenity is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Progenity has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Progenity forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PROG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PROG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PROG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PROG's revenue (18.3% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: PROG's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PROG's Return on Equity is forecast to be high in 3 years time
How has Progenity performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PROG is currently unprofitable.
Growing Profit Margin: PROG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PROG's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PROG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PROG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (59.7%).
Return on Equity
High ROE: PROG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Progenity's financial position?
Financial Position Analysis
Short Term Liabilities: PROG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PROG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PROG has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PROG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PROG has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PROG has less than a year of cash runway if free cash flow continues to reduce at historical rates of 40.5% each year
What is Progenity current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PROG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PROG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PROG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PROG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PROG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Harry Stylli (58 yo)
Dr. Harry Stylli, MBA, PhD is the Founder of Progenity, Inc. and serves as its Chief Executive Officer and Chairman of the Board since August 2018. Dr. Stylli was Executive Chairman of Progenity, Inc. from...
CEO Compensation Analysis
Compensation vs Market: Harry's total compensation ($USD5.75M) is above average for companies of similar size in the US market ($USD540.11K).
Compensation vs Earnings: Harry's compensation has increased whilst the company is unprofitable.
Experienced Management: PROG's management team is considered experienced (2 years average tenure).
Experienced Board: PROG's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: PROG only recently listed within the past 12 months.
Progenity, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Progenity, Inc.
- Ticker: PROG
- Exchange: NasdaqGM
- Founded: 2010
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$142.720m
- Shares outstanding: 60.47m
- Website: https://www.progenity.com
Number of Employees
- Progenity, Inc.
- 4330 La Jolla Village Drive
- Suite 200
- San Diego
- United States
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women ear...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 23:35|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.